Skip to main content
. 2015 Sep;17(5):487–495. doi: 10.1016/j.jmoldx.2015.04.003

Figure 2.

Figure 2

HER2 mutation spectrum in solid tumors. POS, HER2-positive by HER2 fluorescent in situ hybridization or HER2 overexpression by immunohistochemistry (3+).